A groundbreaking study presented at ENDO 2025 reveals that menopause weight loss can be significantly enhanced when combining tirzepatide with menopause hormone therapy, offering new hope for millions of postmenopausal women struggling with obesity and related health complications.
The research, conducted by Mayo Clinic scientists and presented at the Endocrine Society’s annual meeting in San Francisco, demonstrates that postmenopausal women using both treatments simultaneously achieved 17% total body weight loss compared to 14% with tirzepatide alone over an 18-month period.
Revolutionary Treatment Combination Shows Superior Results
Dr. Regina Castaneda, research fellow for the Division of Endocrinology at Mayo Clinic in Jacksonville, Florida, emphasized the significance of these findings. “These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” she stated.
The study involved 120 postmenopausal women, with 40 using menopause hormone therapy concurrently with tirzepatide and 80 using tirzepatide alone. Remarkably, 45% of women using the combination therapy achieved at least 20% total body weight loss, compared to only 18% of those using tirzepatide alone.
This research builds on previous studies with semaglutide that found similar results, suggesting a broader efficacy trend for pairing GLP-1 medications with hormone therapy. The findings could represent a paradigm shift in treating postmenopausal weight gain, a common concern affecting millions of American women.
Addressing Menopause-Related Health Challenges
Menopause-related hormonal changes often result in increased abdominal fat, decreased muscle mass, and altered energy expenditure that leads to weight gain. These changes put millions of women at increased risk for developing heart disease, diabetes, and other serious health complications.
Dr. Maria Daniela Hurtado Andrade, assistant professor of medicine and consultant for the Division of Endocrinology at Mayo Clinic, highlighted the broader implications: “The information garnered through this new study provides important insights to develop more effective and personalized weight management interventions to reduce a postmenopausal woman’s risk of overweight and obesity-related health complications.”
The combination approach addresses multiple physiological changes simultaneously. While tirzepatide helps regulate blood sugar and reduces appetite, menopause hormone therapy can help counteract some of the metabolic changes that occur during menopause, including increased insulin resistance and changes in fat distribution.
Clinical Implications and Future Research
The research was funded by the National Institutes of Health Bridging Interdisciplinary Careers in Women’s Health Research Grant and the Mayo Clinic Center for Women’s Health Research, underscoring the importance of continued investigation in this area.
Dr. Hurtado Andrade stressed the need for continued research: “This study underscores the urgent need for further research to better understand how obesity medications and menopause hormone therapy work together. Gaining this knowledge could greatly improve the health and well-being of millions of postmenopausal women.”
The findings also point to the critical need for better strategies to make these treatments more accessible and available to those who need them. Currently, both tirzepatide and hormone therapy can be expensive, and insurance coverage varies significantly.
Healthcare providers are increasingly recognizing the importance of addressing menopause-related weight gain as a serious health concern rather than an inevitable part of aging. This research provides evidence-based support for combination therapies that could transform treatment approaches.
The study’s real-world design, using electronic medical records rather than controlled clinical trial conditions, adds to its relevance for everyday clinical practice. This approach helps ensure that the findings are applicable to the diverse population of postmenopausal women seeking treatment for weight management.
As the medical community continues to focus on women’s health research, these findings represent a significant step forward in providing effective, evidence-based treatments for postmenopausal women facing weight-related health challenges.